Anbio Biotechnology Class A Ordinary Shares
NASDAQ:NNNNMedical - Instruments & Supplies
+$0.37 today
- Market cap
- $158.01M
- Beta
- 4.34
- P/E (TTM)
- 99.1
- EPS (TTM)
- $0.16
Volume 0.09M
Average 0.03M
NNNN Investing Cash Flow
Net cash used in or generated by investments in assets, acquisitions, and securities.
Anbio Biotechnology Class A Ordinary SharesNASDAQ: NNNN
Investing Cash Flow · Q4 FY2024 · quarter ended Dec 2024
Investing cash flow grows 34.1% year over year
Q4 FY2024 investing cash flow of $215.57K rose 34.1% year over year. Over 3 fiscal years it compounded at +40.1% a year.
Context
- Investing cash flow amounted to 43.1% of revenue in FY2025, up 38.9 pp from a year earlier.
- Investing cash flow increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
Sources:Cash FlowText generated from reported figures; not investment advice.
Investing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (4.2M) USD
- Year-over-year change
- -1346.7%
| Period | Period end | Investing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (4.2M) | -1346.7% |
| FY2024 | 2024-12-31 | 337.1K | -80.5% |
| FY2023 | 2023-12-31 | 1.73M | +213.2% |
| FY2022 | 2022-12-31 | (1.53M) | — |
| FY2021 | 2021-12-31 | 0 | — |
Investing Cash Flow vs competitors
How NNNN compares with its peers on the latest reported figures
- Peers report in different currencies, so investing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -1346.7% is the lowest of 9, against a peer median of +102.3%.
- Investing cash flow amounts to 43.1% of revenue for NNNN, versus a peer median of 8.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $1.43B USD | +435.7% | — | 6.6% | |
| LTM Mar 2026 | $175.9M USD | +1761.3% | — | 316.7% | |
| LTM Mar 2026 | $89.79M USD | +1233.2% | — | 30.0% | |
| LTM Mar 2026 | $59.2M USD | +71.1% | -23.5% | 8.3% | |
| LTM Mar 2026 | $20.65M USD | -62.7% | +350.0% | 8.7% | |
| LTM Dec 2025 | $19.17M USD | — | — | 16.5% | |
| LTM Mar 2026 | CA$11.08M CAD | -130.3% | — | 1.2% | |
| LTM Feb 2026 | $7.3M USD | -26.2% | -19.2% | 2.3% | |
NNNNAnbio Biotechnology Class A Ordinary Shares | FY2025 | $4.2M USD | -1346.7% | +40.1% | 43.1% |
| LTM Mar 2026 | $153K USD | +133.4% | — | 0.4% | |
| LTM Mar 2026 | $0 USD | — | — | — | |
| Peer median (excluding NNNN) | — | +102.3% | -19.2% | 8.3% | |
Competitors are the stored peer set for NNNN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 2.54M | 10.01M | 2.25M | 2.37M | 6.4M |
| Depreciation & Amortization | 0 | 6.25K | 12.06K | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 0 | 0 |
| Change in Working Capital | 1.65M | (5.53M) | (1.2M) | 44.65K | (13.21M) |
| Accounts Receivables | (717.5K) | 717.5K | (1.88M) | 820.17K | (2.59M) |
| Inventory | 0 | (353.87K) | 353.87K | 0 | 0 |
| Accounts Payables | 1.89M | (481.82K) | (580.89K) | 798.1K | (1.63M) |
| Other Working Capital | 473.15K | (5.41M) | 907.97K | (1.57M) | (8.99M) |
| Other Non-Cash Items | 1 | (40.87K) | (163.39K) | (337.1K) | 68K |
| Operating Cash Flow | 4.18M | 4.45M | 898.37K | 2.08M | (6.74M) |
| Capital Expenditures | 0 | (3) | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (16.09M) | (18.54M) | (35.47M) | (19.42M) |
| Sales of Investments | 0 | 14.56M | 20.27M | 35.8M | 15.22M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | (1.53M) | 1.73M | 337.1K | (4.2M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 0 | 0 | 0 | 7.23M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | (42.84K) | (344.61K) | (282.55K) |
| Financing Cash Flow | 0 | 0 | (42.84K) | (344.61K) | 6.95M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 4.18M | 2.92M | 2.59M | 2.07M | (3.99M) |
| Free Cash Flow | 4.18M | 4.45M | 898.37K | 2.08M | (6.74M) |
Anbio Biotechnology Class A Ordinary Shares
NASDAQ:NNNN
Intrinsic Alpha fair value
Locked
Current Price
$3.60
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.